Trial Profile
A Randomised, Double Blind, Placebo Controlled Phase I Study to Investigate the Effects of Systemically Absorbed Cortexolone 17α-propionate (and Its Metabolites) on QT Interval Following Repeat Topical Administration in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Clascoterone (Primary)
- Indications Acne vulgaris; Alopecia
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Cassiopea
- 01 Feb 2019 Status changed from recruiting to completed.
- 19 Sep 2018 New trial record